Poland· PL-100007430

Argosulfan

A sulfathiazole product containing sulfathiazolum argentum, registered in Poland by Bausch+Lomb Ireland Ltd..

ATC D06BA02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedArgosulfanATCD06BA02REGISTER NO.PL-100007430PACKS LISTED3CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Sulfathiazolum argentum
Manufacturer
Bausch+Lomb Ireland Ltd.
Country
Poland (PL)
ATC code
D06BA02
ATC class
Sulfathiazole
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909990237326
  • gtin
    05909990237319
  • gtin
    05904398500010

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2789182f-dc2d-4e72-8b64-ac1c11212c66
GET /v1/drugs/2789182f-dc2d-4e72-8b64-ac1c11212c66?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Krem",
  "source": "urpl",
  "strength": "20 mg/g",
  "packaging": "05909990237326 ¦ Rp ¦ Skasowane ¦ 1132\n1 poj. 400 g\n05909990237319 ¦ Rp ¦ 42050\n1 tuba 40 g\n05904398500010 ¦ Rp ¦ 136097\n1 tuba 100 g",
  "substance": "Sulfathiazolum argentum 20 mg",
  "common_name": "Sulfathiazolum argentum",
  "pl_product_id": "100007430",
  "pozwolenie_nr": "02373",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about sulfathiazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.